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1.1 Rationale for the Consultation
Anaemia is one of the most common and intractable nutritional 
problems in the world today. The World Health Organization (WHO) 
estimates that some two billion people are anaemic defi ned as hae-
moglobin concentrations that are below recommended thresholds. 
The main causes of anaemia are: dietary iron defi ciency; infectious 
diseases such as malaria, hookworm infections and schistosomia-
sis; defi ciencies of other key micronutrients including folate, vita-
min B
12
 and vitamin A; or inherited conditions that affect red blood 
cells (RBCs), such as thalassaemia.
Iron defi ciency with or without anaemia has important conse-
quences for human health and child development: anaemic women 
and their infants are at greater risk of dying during the perinatal 
period; children’s mental and physical development is delayed or 
impaired by iron defi ciency; and the physical work capacity and 
productivity of manual workers may be reduced. There have been 
many efforts to fi ght iron defi ciency and anaemia over the past two 
decades but, despite these efforts, the conditions are still common.
One of the reasons for the apparent failure to reduce the preva-
lence of anaemia is that many programmes and their interven-
tions have been designed with the assumption that the only cause 
of anaemia is iron defi ciency. This has meant that, when trying to 
control anaemia, the role of other causes has been underestimated, 
and that iron defi ciency without anaemia has not been addressed as 
a major and common health problem.
In the absence of international agreement on how to assess the 
iron status of populations, the prevalence of iron defi ciency has 
often been derived from the prevalence of anaemia using measure-
ments of blood haemoglobin concentration. However not all anae-
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mic people are iron defi cient and iron defi ciency may occur without 
anaemia. This means that the prevalence of anaemia and iron defi -
ciency varies in different populations and no consistent relationship 
between the two can be applied throughout the world. When anae-
mia is considered from the point of view of programmes to improve 
nutrition and health, an estimate of the prevalence derived from the 
haemoglobin concentration alone does not allow the contribution 
of iron defi ciency to anaemia to be estimated, and ignores the role of 
other causes of anaemia.
To plan effective interventions to combat both iron defi ciency and 
anaemia there is an urgent need to have better information on the 
iron status of populations. This will enable the right interventions to 
be chosen in the fi rst place and then, once programmes are in place, 
to have the right indicators to monitor their impact.
These were all reasons for holding the Joint WHO/Centers for Dis-
ease Control and Prevention (CDC) Technical Consultation on the 
Assessment of Iron Status at the Population Level. The Consultation 
took place in Geneva, Switzerland, from 6 to 8 April 2004.
1.2 Objectives of the Consultation
The objectives of the Consultation were:
• to review the indicators currently available to assess iron status;
• to select the best indicators to assess the iron status of popula-
tions; 
• to select the best indicators to evaluate the impact of interven-
tions to control iron defi ciency in populations;
• to identify priorities for research related to assessing the iron sta-
tus of populations.
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2. Working defi nitions 
of key terms
For the sake of clarity and to achieve a consensus, several key terms 
were defi ned during the Consultation.
In clinical terms anaemia is an insuffi cient mass of RBCs circu-
lating in the blood; in public health terms anaemia is defi ned as a 
haemoglobin concentration below the thresholds given by WHO, 
UNICEF, UNU (1). These thresholds are set at the 5th percentile 
of the haemoglobin concentration of a normal population of the 
same sex and age group. There is a separate threshold for pregnant 
women. 
Although iron defi ciency is probably the most common cause of 
anaemia, there are other causes as well, including: acute and chron-
ic infections that cause infl ammation; other micronutrient defi cien-
cies, especially of folate, vitamin B
12
 and vitamin A; and genetically 
inherited traits such as thalassaemia. 
Iron defi ciency  is a state in which there is insuffi cient iron to 
maintain the normal physiological function of tissues such as the 
blood, brain, and muscles. Iron defi ciency can exist in the absence 
of anaemia if it has not lasted long enough or if it has not been se-
vere enough to cause the haemoglobin concentration to fall below 
the threshold for the specifi c sex and age group (1). Evidence from 
animals fed on iron-defi cient diets indicates that iron defi ciency 
becomes detectable at about the same time in the blood, brain, and 
tissue enzyme systems (2). 
Storage iron is the pool of iron in the body that is not being used by 
tissues. Healthy children and adults (apart from infants aged 6–11 
months and pregnant women) usually have some iron stores to act 
as a buffer against iron defi ciency during periods when dietary iron 
may be temporarily insuffi cient. Iron depletion is the state in which 
storage iron is absent or nearly absent but the tissues that need iron 
are able to maintain normal physiological functions.
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It is possible for a functional iron defi ciency  to develop even 
when iron stores are present if the normal physiological systems 
for transporting iron to target tissues are impaired. This occurs 
most commonly because of cytokines released during infl amma-
tion caused by infectious diseases, and appears to be mediated by 
hepcidin (3). Iron supplementation or fortifi cation has no benefi t in 
such circumstances. Defi ciencies of other nutrients such as vitamin 
A may also cause a functional iron defi ciency even when iron stores 
are adequate (4). 
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3. Selection of indicators
In January 2004 a WHO/CDC working group met to review the lit-
erature on indicators of iron status and to select the indicators con-
sidered to be the best for discussion by the Consultation. Appendix 
1 shows the indicators considered, each of which was evaluated in 
terms of its theoretical advantage as an indicator of iron status and 
the practicality of its measurement. Appendix 2 shows the fi ve indi-
cators selected to assess iron status and an acute phase protein with 
the methods most commonly used to measure them. The rationale 
for selecting these fi ve was as follows. 
• Haemoglobin concentration is a measure of anaemia, a condition 
that has important outcomes for health and child development 
that are linked to international development goals.
• Zinc protoporphyrin refl ects a shortage in the supply of iron in the 
last stages of making haemoglobin so that zinc is inserted into the 
protoporphyrin molecule in the place of iron. Zinc protoporphy-
rin can be detected in RBCs by fl uorimetry and is a measure of the 
severity of iron defi ciency. 
• Mean cell volume indicates whether RBCs are smaller than usual 
(microcytic), which is a common sign of iron defi ciency anaemia, 
or larger than normal (macrocytic), a common sign of megalob-
lastic anaemia resulting from a defi ciency of vitamin B
12
 or folate.
• Transferrin receptor in serum is derived mostly from develop-
ing RBCs and so refl ects the intensity of erythropoiesis and the 
demand for iron; the concentration rises in iron defi ciency anae-
mia and it is a marker of the severity of iron insuffi ciency only 
when iron stores have been exhausted, provided that there are 
no other causes of abnormal erythropoiesis. The concentration of 
transferrin receptor is also increased in haemolytic anaemia and 
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thalassaemia. Clinical studies indicate that the serum transferrin 
receptor is less affected by infl ammation than serum ferritin (5). 
• Serum ferritin is a measure of the amount of iron in body stores 
if there is no concurrent infection: when the concentration is 
≥15 µg/l iron stores are present; higher concentrations refl ect the 
size of the iron store; when the concentration is low (<12–15 µg/l) 
then iron stores are depleted. When infection is present the con-
centration of ferritin may increase even if iron stores are low; this 
means that it can be diffi cult to interpret the concentration of fer-
ritin in situations in which infectious diseases are common. 
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4. Literature reviews 
The Consultation was provided with literature reviews on indicators 
of iron status, including RBC parameters, ferritin, free erthyrocyte 
protoporphyrin, serum and plasma iron, total iron binding capac-
ity, transferrin saturation and serum transferrin receptor as well as 
a review on the interpretation of indicators of iron status during an 
acute phase response. These reviews, which will be published sepa-
rately, provide technical background to the measurement, biology, 
interpretation and diagnostic value of the indicators. 
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5. Analysis of data from iron 
intervention studies
In order to assess the potential of indicators to detect a change in 
iron status as a result of an intervention, the Consultation reviewed 
the results of an analysis of indicators of iron status and acute phase 
proteins that were measured during 10 double-blind, randomized 
controlled trials. The investigators provided iron either as supple-
ments or as food fortifi ed with iron for periods between 4 and 18 
months to infants (1 study), preschool children (1 study), school-
children (2 studies), pregnant women (2 studies) and non-pregnant 
women (4 studies). The studies were done in Côte d’Ivoire (6), Jamai-
ca (Simmons et al., unpublished data), Morocco (7 ), the Philippines 
(Beard and Haas, unpublished data), one study done in Sweden and 
Honduras (8), one study in the United Republic of Tanzania (9), two 
studies in the United States of America (Beard, unpublished data 
and 10), and two studies in Viet Nam (Thuy et al., unpublished data 
and 11). The original data sets from all trials were provided for this 
analysis by the investigators, who are acknowledged at the end of 
this report. Full details of the analysis will be submitted for publica-
tion in due course. 
The haemoglobin and serum ferritin concentrations were meas-
ured in all ten trials, serum transferrin receptor in nine, zinc pro-
toporphyrin in six, and mean cell volume by fl ow cytometry in four. 
For the nine studies that measured both serum ferritin and transfer-
rin receptor, the body iron stores were estimated using the method 
and constants given by Cook, Flowers, Skikne (12). Because both 
serum ferritin and transferrin receptor concentrations have distri-
butions skewed to the right, both raw values and values transformed 
to logarithms were used in the analysis. 
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5.1 Indicators for evaluating the impact of interventions 
to control iron defi ciency 
The data from the ten studies were selected because the experimen-
tal designs were considered to be adequate (duration of intervention, 
iron dosage and compound) to show an improvement in iron status. 
The data were used to assess how well each indicator predicted the 
changes in iron status. This change was estimated by calculating 
the mean difference between each indicator at the beginning and 
end of each study for the intervention group and then subtracting 
the mean difference calculated for the control group. As each in-
dicator had different units, the net difference between the change 
in the intervention and control groups was divided by the standard 
deviation of the baseline measurement of the indicator calculated 
for both study groups in order to express it in standard deviation 
units (SDUs). For the purposes of analysis an arbitrary change of 
≥0.2 SDUs was defi ned as indicating a successful response to the in-
tervention. A power calculation indicated that this change could be 
detected with a sample size of 400 subjects per study group.
In addition, using the same studies, the change that occurred in 
the subjects with the lowest 10% of values was examined for indica-
tors that were expected to rise, such as haemoglobin concentration, 
and for the highest 10% of values for indicators that were expected 
to fall, such as transferrin receptor. The change in values of these 
10th or 90th percentiles was also expressed as SDUs. This analysis 
was based on the assumption that the most iron defi cient subjects 
would show the greatest change as a result of the interventions. 
Table 1 shows how the indicators performed when assessed in these 
two ways.
An analysis of the effect of using different thresholds of success 
varying between 0.1 and 0.5 SDUs did not change the inferences 
about each indicator in each study. In the one study in which serum 
ferritin did not meet the criterion for success based on the change 
for all subjects, neither did any other indicator. The indicator of body 
iron stores calculated from serum ferritin and transferrin receptor 
did not perform better than serum ferritin alone. It was not possible 
to distinguish between the performance of haemoglobin, transfer-
rin receptor, zinc protoporphyrin and mean cell volume.
5. ANALYSIS OF DATA FROM IRON INTERVENTION STUDIES
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The analysis was based on trials that had a control group to ac-
count for secular and random change. However, many programmes 
simply evaluate differences between before and after an interven-
tion, and do not have a control group in the design. To examine 
whether different indicators would be selected in the absence of a 
control group, two questions were asked.
First, in how many studies did the value of the indicator change in 
the control group by ± 0.2 SDUs? A change of this size in either direc-
tion would imply that the indicator is not very stable. It could also 
indicate an additional source of iron other than the intervention, or 
a change in exposure to hookworms or malaria, that resulted in a 
change in iron status. Second, in how many studies would the wrong 
inference have been made if there had been no control group to ac-
count for secular or random changes?
Four studies were excluded from these analyses because they 
involved pregnant women or young children among whom changes 
would have been expected anyway, without any intervention. Of the 
remaining six studies, which were done among schoolchildren or 
non-pregnant women, mean cell volume was only measured in one 
study and zinc protoporphyrin in two. Table 2 shows the results of 
this analysis, which indicate that serum ferritin and body iron stores 
performed best. 
Table 1 Success of indicators to detect changes in iron status in 10 controlled trials of 
treatments, estimated as the number of indicators showing a change of ≥0.2 standard 
deviation units (SDUs)
Success of indicator Success of indicator 
based on mean change  based on mean change of 
Indicator of of ≥ 0.2 SDUs for all ≥ 0.2 SDUs for top or 
iron status subjects bottom 10%a
Haemoglobin 60%, 6 of 10 studies 80%, 8 of 10 studies
Mean cell volume 50%, 2 of 4 studies 75%, 3 of 4 studies
Serum ferritinb 90%, 9 of 10 studies 60%, 6 of 10 studies
Transferrin receptorc 56%, 5 of 9 studies 56%, 5 of 9 studies
Body iron stores 78%, 7 of 9 studies 78%, 7 of 9 studies
Zinc protoporphyrin 50%, 3 of 6 studies 67%, 4 of 6 studies
a Depends on whether the indicator was expected to rise or fall.
b Transformed to logarithms.
c Results were the same with or without transforming values to logarithms.
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Based on results of the analysis presented in Table 1 and 2, it was 
concluded that serum ferritin is the indicator of choice to evaluate 
the impact of interventions to control iron defi ciency in studies with 
or without control groups.
5.2 Performance of indicators to predict a 
change in haemoglobin concentration in 
response to iron intervention
A critical issue for the Consultation was to decide which current in-
dicator represents the best means to identify a true iron defi ciency 
and could act as the “gold standard” by which to evaluate alterna-
tive indicators. The change in haemoglobin concentration following 
intervention using iron was chosen based on the assumption that 
the size of any change was likely to be strongly related to the degree 
of iron defi ciency. This measure has been used in previous studies 
(13). It has a disadvantage because if factors other than iron defi -
ciency contribute to anaemia, such as a vitamin A defi ciency, then 
the haemoglobin concentration will not respond to treatment with 
iron alone.
A linear regression analysis was performed to examine the degree 
to which baseline indicators of iron status predict a change in hae-
moglobin, using the following model:
Table 2 The results of an analysis of the stability of indicators of iron status in control 
groups during studies of interventions and of the inferences that would have been wrong 
without a control group
Number of studies in which Number of studies in which 
there was a signifi cant  the inference would have 
Indicator of change in the control group  been wrong without a 
iron status of ± 0.2 SDUs a control group
Haemoglobin 4 of 6 2 of 6
Serum ferritin 1 of 6 1 of 6
Transferrin receptor 3 of 6 2 of 6
Body iron stores 1 of 6 1 of 6
Zinc protoporphyrin 2 of 2 1 of 2
SDUs, Standard deviation units.
5. ANALYSIS OF DATA FROM IRON INTERVENTION STUDIES



















Where: Y is the change in haemoglobin concentration from
baseline to follow-up 
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 is the group (control versus intervention)
X
2





 is the interaction between group and iron indicator
ε is the error or residual.
The coeffi cient of interest in this analysis is (β
3
) defi ned as the excess 
change in haemoglobin concentration for intervention over control 
for each additional SDU of the selected iron indicator at baseline. A 
statistically signifi cant interaction term (β
3
) was interpreted to mean 
that the indicator was associated with a change in haemoglobin con-
centration in response to intervention with iron, whether given as 
supplements or as fortifi ed food. An indicator was arbitrarily classi-
fi ed as successful if there was an increase in haemoglobin concen-
tration by ≥3 g/l for each SDU of the selected indicator at baseline. 
An advantage of this approach is that it uses the control group to 
take into account both secular trends in haemoglobin concentra-
tion and regression to the mean. Variables that were not normally 
distributed were transformed to logarithms to see if their predictive 
power could be improved.
Table 3 shows the success of each indicator in predicting the 
change in haemoglobin concentration in response to an iron in-
tervention. Using an increase of 2–5 g/l made no difference to the 
results of the analysis.
Table 3 The success rate of indicators of iron status to predict an increase in 
haemoglobin of ≥3 g/l for each standard deviation unit of the indicator at baseline 
Indicator of iron status Success rate
Haemoglobin 10%, 1 of 10 studies
Mean cell volume 25%, 1 of 4 studies
Serum ferritina 40%, 4 of 10 studies
Transferrin receptor 33%, 3 of 9 studies
Body iron stores 44%, 4 of 9 studies
Zinc protoporphyrin 17%, 1 of 6 studies
a Transformed to logarithms. 
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Table 3 shows that the indicators were generally less successful 
in predicting the response of the haemoglobin concentration to 
treatment with iron than in assessing the response to interventions 
shown in Table 1. In fact in six of the ten studies, including the three 
studies in Africa, none of the indicators were associated with the 
change in haemoglobin concentration. This could have been be-
cause low haemoglobin concentrations were caused by factors other 
than iron defi ciency, such as infectious diseases, which impaired 
the haemoglobin response to the interventions. Nevertheless, this 
analysis led to the following tentative conclusion, that serum ferritin 
or transferrin receptor are the best indicators to predict a change in 
haemoglobin concentration in response to iron intervention and, 
if both indicators are measured, then body iron stores can be esti-
mated as well. But these indicators were successful in less than half 
of the studies analysed.
5. ANALYSIS OF DATA FROM IRON INTERVENTION STUDIES
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6. Indicators of 
infl ammation
The Consultation considered that serum ferritin was the best indi-
cator of the impact of an iron intervention as well as being a useful 
indicator of depleted iron stores. However serum ferritin is also an 
acute phase protein, which means that its concentration rises dur-
ing infl ammation, so the customary thresholds to indicate an iron 
defi ciency of <12–15 µg/l may no longer apply. One way of dealing 
with this issue is to set the threshold higher, and a threshold of 
<30 µg/l has been recommended in the presence of infection, but 
only for children <5 years old (1). There is a need to examine the 
value of using different thresholds among infected older children 
and adults.
The Consultation proposed that the measurement of an acute 
phase protein could help to interpret data on serum ferritin: if the 
concentration of the additional acute phase protein is higher than 
the normal threshold it could indicate underlying infl ammation and 
explain a high serum ferritin concentration in the presence of iron 
defi ciency.
One way of controlling for a high serum ferritin concentration re-
sulting from infection would be to use the concentration of another 
acute phase protein to exclude individuals whose measurements 
of both indicators are above a certain threshold. This approach is 
not considered feasible in many parts of sub-Saharan Africa where 
many people are infected with Plasmodium spp., the cause of 
malaria, and are either asymptomatic or have only mild disease and 
yet have high concentrations of acute phase proteins in their blood 
(14). Many of the same individuals may also be chronically infected 
with one or more species of worms, which may also contribute to 
an acute phase response as well as to anaemia and iron defi ciency 
because of the blood loss they cause. There may even be an acute 
phase response without a loss of blood. Excluding individuals with 
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high concentrations of acute phase protein may, in circumstances in 
which repeated or chronic infections are common, reduce the sam-
ple size substantially and leave an atypical residual sample.
The Consultation felt that there was a need for the analysis of data 
on the relationship between serum ferritin, transferrin receptor and 
different acute phase proteins to assess which was best correlated 
with serum ferritin during different stages of infection. For example, 
it may be possible to control for high serum ferritin concentrations 
using one or more acute phase proteins. Several acute phase proteins 
could be used for this purpose including C-reactive protein (CRP), 
α-1-antichymotrypsin (ACT), α-1 acid glycoprotein (AGP), serum 
amyloid A, fi brinogen and haptoglobin. The most frequently used 
acute phase proteins are CRP, which responds quickly to infl amma-
tion but also subsides quickly in concentration; ACT which also rises 
quickly but remains at a high concentration longer than CRP; and 
AGP which is slower to respond than CRP or ACT but remains at a 
high concentration for longer than either (15,16). The concentration 
of AGP maybe a better indicator than CRP or ACT of the presence of 
chronic, sub-clinical infection, and may better refl ect the changes 
in the concentration of ferritin during infections.
The Consultation proposed that data should be sought from stud-
ies in diverse settings that have, if possible, measured haemoglobin 
concentration, serum ferritin and transferrin receptor, and at least 
one acute phase protein, with CRP, ACT and AGP as the fi rst choices. 
Because an assay for transferrin receptor has only relatively recently 
become available, data sets that do not include this measurement 
but have measured another acute phase protein as well as serum 
ferritin would also be useful. Data on the presence of infectious dis-
eases or on malaria parasitaemia, and on the intensity of worm in-
fections would also be helpful to examine the relationship between 
specifi c infections and acute phase proteins.
6. INDICATORS OF INFLAMMATION
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7.  Recommendations 
The Consultation made the following recommendations based on 
the analysis of studies presented, the literature reviews, and on the 
debates during the Consultation.
7.1 Assessing the iron status of populations
The concentration of haemoglobin should be measured, even 
though not all anaemia is caused by iron defi ciency. The prevalence 
of anaemia is an important health indicator and when it is used with 
other measurements of iron status the haemoglobin concentration 
can provide information about the severity of iron defi ciency.
Measurements of serum ferritin and transferrin receptor provide 
the best approach to measuring the iron status of populations. In 
places where infectious diseases are common, serum ferritin is not 
a useful indicator because infl ammation leads to a rise in the con-
centration of serum ferritin as a result of the acute phase response 
to disease. If infectious diseases are seasonal, then the survey 
should be done in the season of lowest transmission. In general the 
concentration of transferrin receptor does not rise in response to 
infl ammation so that, when combined with the concentration of 
serum ferritin, it is possible to distinguish between iron defi ciency 
and infl ammation. Table 4 indicates how data on serum ferritin and 
transferrin receptor may be interpreted based on the experience of 
participants of the Consultation. For the purposes of describing the 
prevalence of iron defi ciency in a population with a single number, 
the prevalence based on serum ferritin should be used except where 
infl ammation is prevalent (Table 4, row 2) in which case the preva-
lence based on transferrin receptor is more appropriate. However, 
the proposed classifi cation still requires validation in population 
surveys. 
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Table 4 The interpretation of low serum ferritin and high transferrin receptor 
concentrations in population surveys: this classifi cation is based on experience of 
measuring ferritin and transferrin receptor in research studies and requires 
validation in population surveys 
Percentage of Percentage of
serum ferritin values  transferrin receptor
below thresholda values above thresholdb Interpretation
<20%c <10% Iron defi ciency is not prevalent.
<20%c ≥10% Iron defi ciency is prevalent; 
   infl ammation is prevalent. 
≥20%d ≥10% Iron defi ciency is prevalent.
≥20%d <10% Iron depletion is prevalent.
a Apply thresholds by age group given in WHO, UNICEF, UNU (1).
b Apply thresholds recommended by manufacturer of assay until an international reference standard is available 
(See Section 8, Priorities for research, below).
c <30% for pregnant women.
d ≥30% for pregnant women.
Studies are needed to determine the best procedures to process, 
transport and store biological samples in which transferrin recep-
tor will be measured, and to establish internationally applicable 
thresholds to classify the iron status of populations.
It can be useful also to measure the concentration of an acute 
phase protein, if funding is available. The most commonly meas-
ured acute phase protein is CRP, but there is evidence that AGP may 
better refl ect the change in concentration of ferritin in serum and 
may be the most useful acute phase protein to measure. A number 
of commercial assays are available for measuring these proteins but, 
except for CRP, there are no international reference standards avail-
able, resulting in reference ranges specifi c to each assay. In such 
circumstances, the threshold recommended by the manufacturer 
should be used.
7.2 Evaluating the impact of interventions to control 
iron defi ciency in populations
Serum ferritin is the best indicator of a response to an interven-
tion to control iron defi ciency and should be measured with the 
haemoglobin concentration in all programme evaluations. In cir-
cumstances in which iron defi ciency is the major cause of anaemia, 
7.  RECOMMENDATIONS 
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the haemoglobin concentration may improve more rapidly than the 
serum ferritin concentration. In circumstances in which the serum 
ferritin concentration improves (even when infl ammation is com-
mon) but the haemoglobin concentration does not, factors in addi-
tion to iron are likely to be the cause of anaemia.
If funding is available, it could also be useful to measure the con-
centration of one or both of the acute phase proteins CRP or AGP, to 
account for a high serum ferritin concentration caused by infl am-
mation. Individuals with high values for the acute phase protein 
should be excluded from the analysis, if possible, depending on 
the limitations imposed by the sample size of the dataset and the 
consequent translation of the results to defi ne the iron status of the 
general population. This is particularly important when repeated 
surveys are done and there is no control group for the intervention.
If funding is available, the transferrin receptor should be meas-
ured during repeated surveys to classify populations according to 
the criteria shown in Table 4. The combination of serum ferritin and 
transferrin receptor may also be used to estimate body iron stores in 
populations (12). The calculation of body iron stores is not essential 
but can be useful to estimate the amount of iron that is absorbed 
during an intervention and to demonstrate a decrease in iron de-
fi ciency. However, since the method uses measurements of serum 
ferritin concentration, infection may again be a confounding factor, 
so an acute phase protein should be measured to exclude individu-
als with a high concentration.
A working group will be established to coordinate the analysis of 
data sets containing estimates of serum ferritin, transferrin recep-
tor and acute phase proteins and to make suggestions about how to 
improve the assessment of iron status. 
In three years time, another consultation will be held to evalu-
ate the recommendations made here based on the results of recent 
studies of assessing iron status. 
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8. Priorities for research
• There is an urgent need for an international reference material 
with a certifi ed concentration of transferrin receptor to standard-
ize transferrin receptor assays. 
• A review of existing data is needed to confi rm the thresholds used 
in Table 4 to derive a classifi cation of iron status. The analysis 
should also examine alternative approaches using serum ferri-
tin alone, and with one or two acute phase proteins. Thresholds 
for other indicators of iron status, such as zinc protoporphyrin, 
should also be examined if possible.
• A review of existing data is needed to examine which acute phase 
proteins might best be used to interpret data on serum ferritin 
during both acute and chronic infections, and whether data on 
serum ferritin could be corrected rather than excluded. This re-
view would identify the best acute phase protein to use and the 
thresholds to apply for both the acute phase protein and serum 
ferritin, in health and during infection.
• There is a need for simple instruments that can be used in the 
fi eld to measure indicators of iron status such as ferritin, transfer-
rin receptor or acute phase proteins, or simple methods to collect 
samples for analysis, such as dried spots of blood or serum. 
• The thresholds and ranges for all indicators of iron status need to 
be defi ned and validated for children aged 6–24 months. 
• Controlled studies are needed to further examine how body iron 
stores that have been estimated using the ratio between transfer-
rin receptor and ferritin change in response to interventions to 
improve iron status.
• Additional iron intervention studies are required to assess the 
validity of the recommended indicators.
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APPENDIX 2
